2Yang C,Yu C,Chen K,et al.A phase Ⅱ study of gefitinib as first line treatment for good performance advanced or metastatic non-small cell lung cancer in East Asian patients[J].J Clin Oncol,2006,24(18s):405.
3Cadranel J,Quoix E,Debove P,et al.IFCT0401 trial:Phase Ⅱ study of gefitinib administered as first line treatment in non-resectable,pneumonic-type adenocarcinoma (P-ADC)[J].J Clin Oncol,2006,24(18s):410.
4Nokihara H,Ohe Y,Kawaishi M,et al.A randomized phase Ⅱ study of sequential carboplatin/paclitaxel (CP) and gefitinib (G) in chemotherapy-nave patients with advanced non-small-cell lung cancer (NSCLC):Preliminary results[J].J Clin Oncol,2006,24(18s):388.
5Takano T,Ohe Y,Furuta K,et al.EGFR mutations detected by high-resolution melting analysis (HRMA) as a predictor of response and survival in non-small cell lung cancer (NSCLC) patients treated with gefitinib[J].J Clin Oncol,2006,24(18s):382.
6Sunaga N,Yanagitani N,Kaira K,et al.Phase Ⅱ study of the efficacy of gefitinib in patients with non-small cell lung cancer with the EGFR mutations[J].J Clin Oncol,2006,24(18s):409.
7Wu Y,Zhong W,Li L,et al.EGFR mutations and the correlation with gefitinib therapy in Chinese NSCLC-A systematic review based on individual patient data from 5 medical centers in China[J].J Clin Oncol,2006,24(18s):410.
8Funada Y,Satouchi M,Miyagawa T,et al.The predictive factors and patient-selection associated with the survival benefits of gefitinib in patients with advanced non-small cell lung cancer (NSCLC)[J].J Clin Oncol,2006,24(18s):668.
9Hirsch FR,Franklin WA,McCoy J,et al.Predicting clinical benefit from EGFR TKIs:Not all EGFR mutations are equal[J].J Clin Oncol,2006,24(18s):382.
10Van ZN,Mathy A,Boerrigter L,et al.EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors:retro-and prospective observations in non-small-cell lung cancer[J].Ann Oncol,2007,18(1):99-103.
